You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

ZUG, Switzerland, Feb. 1, 2021 /PRNewswire/ --Pharvaris, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the release of a late-breaker abstract that will be presented at the 2021 American Academy of Allergy Asthma & Immunology (AAAAI) Virtual Annual Meeting, to be held Feb. 26 through March 1, 2021. The presentation details are as follows: Title: PHA-022121: A Novel and Potent Bradykinin 2 Receptor Antagonist for Oral Treatment of Hereditary AngioedemaPoster Number: L23Poster Presenter: Raf Crabb, M.D. The abstract will be published in the February 2021 online supplement of The Journal of Allergy and Clinical Immunology. About Pharvaris Pharvaris is a clinical-stage biopharmaceutical company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit https://pharvaris.com/. Investor ContactChad Rubin, Solebury Trout[emailprotected] Media ContactMaggie Beller, Russo Partners, LLC[emailprotected]+1-646-942-5631 SOURCE Pharvaris

Answer: Pharvaris to Present Clinical Data of PHA121 for the Treatment of Hereditary Angioedema at the 2021 AAAAI Annual Meeting